Fifty years ago, only half of the patients diagnosed with cancer in the United States would have been alive five years later.
By 2009, patient survival climbed to 70%. The problem is, in all our years working in the pharmaceutical industry and oncology, commercialization has not evolved with science.
Manufacturers preparing for launch probably only see three options: sell their product to a big box pharmaceutical company, license or co-promote their product to a company with an established infrastructure, or launch internally with their own team. However, today’s unpredictable landscape, coupled with inevitable industry pressures, is forcing manufacturers to seek a more complete commercialization approach with less risk and more value.
Now, there’s a new option: EVERSANA’s end-to-end, integrated model, EVERSANA COMPLETE Commercialization™, is uniquely designed to address challenges in the oncology pipeline with agility and data-driven solutions. With an infrastructure based on product and patient needs, COMPLETE Commercialization provides manufacturers the flexibility and expertise to customize their strategies and build functional service areas for a successful launch.
Download the white paper to learn more.
Author
Vice President, Oncology Key Accounts
Glenn brings more than 35 years of experience to EVERSANA’s team of experts who are addressing unique oncology challenges with agility and data-driven solutions. Throughout his career in executive-level roles, Glenn has become an…